更昔洛韦联合思密达治疗轮状病毒肠炎56例效果分析

将收治的轮状病毒肠炎婴幼儿120例随机分为2组,对照组64例,使用更昔洛韦5～10mg/(kg·d)静脉滴注;观察组56例,更昔洛韦5～10 mg/(kg·d)静脉滴注,同时口服思密达,每次1/3包,3次/d。治疗后,对照组和观察组总有效率分别为62.50%(40/64)和89.29%(50/56),差异有统计学意义(P<0.05)。表明更昔洛韦联合思密达治疗婴幼儿轮状病毒肠炎疗效显著,值得推广。     

Genetic analysis of PRRT2 for benign infantile epilepsy,infantile convulsions with choreoathetosis syndrome,and benign convulsions with mild gastroenteritis

Purpose: PRRT2 mutations were recently identified in benign familial infantile epilepsy (BFIE) and infantile convulsions with paroxysmal choreoathetosis (ICCA) but no abnormalities have so far been identified in their phenotypically similar seizure disorder of benign convulsions with mild gastroenteritis (CwG), while mutations in KCNQ2 and KCNQ3 have been recognized in benign familial neonatal epilepsy (BFNE). The aim of this study was to identify PRRT2 mutations in infantile convulsions in Asian families with BFIE and ICCA, CwG and BFNE. Methods: We recruited 26 unrelated Japanese affected with either BFIE or non-familial benign infantile seizures and their families, including three families with ICCA. A total of 17 Japanese and Taiwanese with CwG, 50 Japanese with BFNE and 96 healthy volunteers were also recruited. Mutations of PRRT2 were sought using direct sequencing. Results: Heterozygous truncation mutation (c.649dupC) was identified in 15 of 26 individuals with benign infantile epilepsy (52.1%). All three families of ICCA harbored the same mutation (100%). Another novel mutation (c.1012+2dupT) was found in the proband of a family with BFIE. However, no PRRT2 mutation was found in either CwG or BFNE. Conclusions: The results confirm that c.649dupC, a truncating mutation of PRRT2, is a hotspot mutation resulting in BFIE or ICCA regardless of the ethnic background. In contrast, PRRT2 mutations do not seem to be associated with CwG or BFNE. Screening for PRRT2 mutation might be useful in early-stage differentiation of BFIE from CwG.     

Comparison between febrile and afebrile seizures associated with mild rotavirus gastroenteritis

PurposeWe aimed on identifying the differences of febrile and afebrile seizures associated with mild rotavirus gastroenteritis (RVGE) in the pediatric population.MethodMedical charts of pediatric patients who had been admitted between July 1999 and June 2011 due to RVGE were retrospectively reviewed. Subjects were ultimately divided into three groups; ‘no seizure’ (NS: patients without seizure), ‘febrile seizure’ (FS: patients with fever during seizure), ‘afebrile seizure’ (AFS: patients without fever during seizure). Comparisons between groups were carried out on demographic and clinical characteristics, laboratory test results, electroencephalogram findings, brain magnetic resonance imaging findings, antiepileptic treatment, and prognosis.ResultsAmong the 755 subjects who had been admitted due to mild rotavirus enteritis, 696 (90.3%) did not have any seizures, 17 (2.2%) had febrile seizures, 42 (5.5%) had afebrile seizures. The duration of gastrointestinal symptoms before the onset of seizures were significantly shorter in the FS group compared to the AFS group (1.3 ± 0.8 vs. 2.8 ± 1.0 days; p < 0.0001). A single seizure attack was significantly higher in the AFS group (3.0 ± 1.6 vs. 1.7 ± 1.0 episodes; p = 0.0003), and the frequency of seizures that were of focal type with or without secondary generalization were significantly higher in the AFS group (33.3% vs. 6.0%; p = 0.0139). All patients among the FS and AFS group had not received further antiepileptic treatment after discharge, and none developed epilepsy during follow up period.ConclusionDespite some differences in seizure characteristics, both febrile and afebrile seizures associated with mild RVGE were mostly benign with a favorable prognosis.     

2007-2021年我国诺如病毒急性胃肠炎暴发疫情流行特征及影响因素分析

目的 分析我国诺如病毒急性胃肠炎暴发疫情流行病学特征,探讨暴发疫情规模的影响因素,为及早控制暴发疫情提供科学依据。方法 对突发公共卫生事件管理信息系统2007年1月1日至2021年12月31日全国诺如病毒急性胃肠炎暴发疫情进行描述性流行病学分析,应用非条件logistic回归模型分析暴发疫情规模的影响因素。结果 2007-2021年共报告暴发诺如病毒急性胃肠炎疫情1 725起,报告疫情起数呈上升趋势。南方省份每年10月至次年3月为疫情高峰,北方省份疫情高峰为每年10-12月和次年3-6月。疫情报告地区从东南沿海省份逐步向中部、东北和西部省份扩散。疫情主要发生在学校和托幼机构（1 539起,89.22%）,其次为企事业单位（67起,3.88%）和社区家庭（55起,3.19%）。人与人接触为主要传播途径1 262起（73.16%）,GⅡ基因型为引起暴发疫情的主要病原型别（899起,81.58%）。首例病例发病至疫情报告时间间隔M（Q₁,Q₃）为3（2,6）d,疫情规模M（Q₁,Q₃）为38（28,62）例。近年来,疫情报告及时性提升,疫情规模随年份呈下降趋势,二者在不同发生场所之间差异均有统计学意义（P<0.001）。发生场所、传播途径、报告及时性和居住地类型是暴发疫情规模的影响因素（P<0.05）。结论 2007-2021年我国诺如病毒急性胃肠炎暴发疫情整体呈上升趋势,疫情波及地区范围不断扩大,但疫情发生规模整体呈下降趋势,疫情报告及时性提升,提高监测灵敏度和及早报告可有效控制疫情发生规模。     

上海市浦东新区2012-2013年病毒性腹泻检测情况分析

目的 了解上海市浦东新区2012-2013年间常见病毒性腹泻的病原学特征,为腹泻病的防控提供依据.方法 收集2012-2013年上海市浦东新区14家监测医院腹泻患者的粪便标本,采用实时荧光定量-聚合酶链式反应(real-time PCR)检测轮状病毒、诺如病毒GⅠ型、诺如病毒GⅡ型、星状病毒、扎如病毒和肠腺病毒.结果 共检测粪便样本4 214份.1 255份样本检出至少1种病毒核酸,核酸阳性检出率为29.78％.轮状病毒、诺如病毒GⅠ型、诺如病毒GⅡ型、扎如病毒、星状病毒以及肠腺病毒的检出率分别为7.6％、1.4％、18.6％、1.6％、1.5％和1.1％.各年龄组均有病毒检出,其中年龄最小的为1岁,最大为92岁,分别为感染轮状病毒和诺如病毒.病毒性腹泻感染不存在男女差异,但不同年龄组的病毒性腹泻感染有差异.不同病毒病原的感染存在不同的高峰期,但主要集中在秋冬季.结论 诺如病毒和轮状病毒是浦东地区病毒性腹泻的主要病原.应该加强对病毒性腹泻的监测,尤其是诺如病毒和轮状病毒.     

A nano silicon adjuvant enhances inactivated transmissible gastroenteritis vaccine through activation the Toll-like receptors and promotes humoral and cellular immune responses

Inactivated transmissible gastroenteritis virus (TGEV) vaccines are widely used in swine herds in China. These are limited, however, by the need to elicit both humoral and cellular immunity, as well as the efficiency of adjuvants. In this study, a 70-nm nano silicon particle was applied with inactivated TGEV vaccine in mice, and its immune-enhancing effects and mechanism of action investigated. We found that nano silicon applied with inactivated TGEV vaccine induced high antibody titers, increase IL-6, TNF-α and IFN-γ expression, and stimulate CD3+ T cell proliferation with a high CD4+/CD8+ T lymphocyte ratio. Nano silicon could quickly activate innate and adaptive immunity by stimulating Toll-like receptor signaling pathways, indicating that the nano silicon adjuvant enhanced long-term humoral and early cellular immune responses when combined with inactivated TGEV vaccine. Nano silicon could be considered for use as an antigen- carrier and adjuvant for veterinary vaccines.     

Protein deficiency reduces efficacy of oral attenuated human rotavirus vaccine in a human infant fecal microbiota transplanted gnotobiotic pig model

BackgroundLow efficacy of rotavirus (RV) vaccines in developing African and Asian countries, where malnutrition is prevalent, remains a major concern and a challenge for global health.MethodsTo understand the effects of protein malnutrition on RV vaccine efficacy, we elucidated the innate, T cell and cytokine immune responses to attenuated human RV (AttHRV) vaccine and virulent human RV (VirHRV) challenge in germ-free (GF) pigs or human infant fecal microbiota (HIFM) transplanted gnotobiotic (Gn) pigs fed protein-deficient or -sufficient bovine milk diets. We also analyzed serum levels of tryptophan (TRP), a predictor of malnutrition, and kynurenine (KYN).ResultsProtein-deficient pigs vaccinated with oral AttHRV vaccine had lower protection rates against diarrhea post-VirHRV challenge and significantly increased fecal virus shedding titers (HIFM transplanted but not GF pigs) compared with their protein-sufficient counterparts. Reduced vaccine efficacy in protein-deficient pigs coincided with altered serum IFN-α, TNF-α, IL-12 and IFN-γ responses to oral AttHRV vaccine and the suppression of multiple innate immune parameters and HRV-specific IFN-γ producing T cells post-challenge. In protein-deficient HIFM transplanted pigs, decreased serum KYN, but not TRP levels were observed throughout the experiment, suggesting an association between the altered TRP metabolism and immune responses.ConclusionCollectively, our findings confirm the negative effects of protein deficiency, which were exacerbated in the HIFM transplanted pigs, on innate, T cell and cytokine immune responses to HRV and on vaccine efficacy, as well as on TRP-KYN metabolism.     

Rotavirus diarrhoea hospitalizations among children under 5 years of age in Nigeria, 2011–2016

BackgroundThe high burden of rotavirus acute gastroenteritis (AGE) is well documented among children under 5 years of age, with the majority of mortality occurring in developing countries. Nigeria ranked second worldwide in the number of rotavirus deaths in 2013. As Nigeria plans to introduce rotavirus vaccine soon, a pre-vaccine documentation of rotavirus disease burden is necessary to determine vaccine impact.MethodsRoutine rotavirus surveillance was conducted during 2011–2016 in 3 sentinel sites in Nigeria using the standard WHO protocol. Children under 5 years of age hospitalized for acute gastroenteritis were enrolled and demographic, clinical and outcome data were collected. A stool sample was subsequently obtained and tested for human rotavirus antigen using the Enzyme-linked immunosorbent assay (ELISA).Results2694 children with acute gastroenteritis were enrolled during January 2011 to December 2016; of these, 1242 (46%) tested positive for rotavirus. Among the rotavirus positive cases, 66% and 94% were younger than 12 months and 24 months respectively. Marked peaks in rotavirus positivity were seen in January of each year. Vomiting, and use of oral and intravenous fluids occurred more often in rotavirus positive cases as compared to rotavirus negative cases.ConclusionThe high prevalence of rotavirus disease highlights the need for urgent introduction of rotavirus vaccine in Nigeria. Additionally, this study provides pre-vaccine introduction disease-burden data that will serve as a baseline for rotavirus vaccine impact-assessment once vaccine has been introduced in the national immunization program.     

Genotype distribution of Group A rotavirus from southern India, 2005–2016

Diarrheal disease due to Group A rotaviruses remain a leading cause of mortality and morbidity in the less developed parts of the world. India has started a phased roll out of rotavirus vaccine in the national immunization program. This analysis summarizes the rotavirus genotype strain distribution pre-vaccine introduction in Vellore, India from December 2005 to June 2016. Rotavirus was responsible for 32% of all diarrheal admission to the hospital. G2P[4] was the predominant strain in the initial years and was gradually replaced by G1P[8]. The emergence of G9P[4] replacing G9P[8], and the detection of G12 strains over several years were documented. There was no clear seasonality of disease. These data form the baseline to monitor genotype distribution post-vaccine introduction in Tamil Nadu.     

Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit: Review of available evidence

Rotavirus (RV) is the leading cause of severe acute gastroenteritis (GE) in infants worldwide. Several vaccines against RV were developed to reduce disease burden, hospitalization rates and health utilization costs. RV GE is a serious disease in preterm (PT) infants, and the administration of RV vaccine to these at-risk subjects at the proper time could have great clinical relevance. However, most data on the efficacy and safety of RV vaccinations were collected in healthy full-term infants, and few studies investigated PT infants. The lack of studies in PT infants may explain why neonatologists in several neonatal intensive care units (NICUs) do not follow the official recommendations, which indicate that RV vaccine may be administered in hospitals. Increasing neonatologists’ knowledge on the efficacy and safety of RV vaccines and defining PT candidates for vaccination and the necessary precautions are extremely important to avoid potential vaccine virus transmission and improve RV vaccination coverage in PT infants. Further studies should analyse the impact of vaccination of PT infants of different gestational ages and various clinical histories in stable conditions in the NICU with a careful monitoring of adverse events to the vaccine and RV GE occurrence. Only data that confirm the efficacy and safety of RV vaccines in large numbers of PT infants with different characteristics will convince neonatologists to use RV vaccines in PT infants hospitalized in NICUs.